Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of PBI-200 in Subjects With NTRK-Fusion-Positive Advanced or Metastatic Solid Tumors

NCT04901806 is registered in ClinicalTrials.gov with Pyramid Biosciences as lead sponsor.

NCT NCT04901806
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04901806 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of PBI-200 in Subjects With NTRK-Fusion-Positive Advanced or Metastatic Solid Tumors
Lead sponsor
Pyramid Biosciences
Phase
Phase 1
Overall status
Terminated
Start date
July 20, 2021
Completion date
July 26, 2023
Enrollment
29 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

brain tumor, primary, desmoplastic small round cell tumor, solid tumor, adult